Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

be applicable for the full year ending December 31, 2014.

AbbVie has prepared the AbbVie Profit Forecast based on unaudited interim financial results for the six months ended June 30, 2014 and a forecast to September 30, 2014 and December 31, 2014.

3.
AssumptionsAbbVie has prepared the AbbVie Profit Forecast on the basis of the following assumptions:

Factors outside the influence or control of AbbVie and its Directors

  • There will be no material change to the existing prevailing global macroeconomic and political conditions during the year ended December 31, 2014.
  • The Euro, British pound and Japanese yen and other exchange rates, and inflation and tax rates in AbbVie's principal markets will remain materially unchanged from the prevailing rates.
  • There will be no material change in legislation or regulatory requirements impacting on AbbVie's operations or its accounting policies.
  • There will be no material change in AbbVie's labour costs, including medical and pension and other post-retirement benefits driven by external parties or regulations.
  • There will be no material adverse events that will have a significant impact on AbbVie's financial performance.
  • Factors within the influence or control of AbbVie and its Directors

  • The AbbVie Profit Forecast excludes any material acquisitions or disposals in the year ended December 31, 2014.
  • This AbbVie Profit Forecast excludes any future one-time costs associa
    '/>"/>

  • SOURCE AbbVie
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. AbbVie to Host Second-Quarter Earnings Conference Call
    2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
    3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
    4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
    5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
    6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
    7. AbbVie Reports Third-Quarter 2013 Financial Results
    8. AbbVie Named a Science Top Employer
    9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... 2015 Thirty-six million Americans suffer from hearing ... – National Hearing Month – more than 28 million ... on the sounds of spring, like birds singing and ... ensure that you won,t be among those missing out ... Inc. offers practical advice: Take action if ...
    (Date:5/4/2015)... 4, 2015 Southfield Capital, a ... announced today that it completed a dividend ... specializes in the development and multi-channel deployment ... and biotechnology industries. Through the ... half of their invested capital and secured ...
    (Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
    Breaking Medicine Technology:It's Better Hearing Month 2Southfield Capital and BioPharm Communications Announce Dividend Recapitalization 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
    ... , FRANKLIN LAKES, N.J. , ... BDX ), a leading global medical technology company, is increasing ... Haiti earthquake relief efforts from the $500,000 ... in market value of critical medical supplies.  This additional commitment will ...
    ... , Jan. 27 CardioGenics Holdings Inc. (OTC ... the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, ... self-metering cartridge for its POC diagnostic device, the QL Care ... the self-metering cartridge. , Dr. Yahia Gawad , CEO ...
    Cached Medicine Technology:BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 2BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 3CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 2CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 3
    (Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
    (Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
    (Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
    (Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
    (Date:5/4/2015)... May 04, 2015 The opportunity for children ... life are the motivating forces behind The Fairy Godmother Next ... and author Amy L. Stark. , The inspiration for the ... next door comes from Stark’s desire to be a fairy ... a fairy godmother to my neighbors’ children since they were ...
    Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
    ... Ustekinumab injections every 3 months a more convenient ... News) -- The drug ustekinumab has been shown to ... moderate-to-severe psoriasis in two studies published in this week,s ... by binding to two interleukins, proteins produced by the ...
    ... leadership in proposing prescription,drug marketing reform and transparency, ... believes,New York has a paramount interest in passing ... undue influence that,pharmaceutical companies have over prescribing decisions ... treatment they receive., The reforms include banning ...
    ... worldwide cancer incidence, researchers at the Moores Cancer Center ... Department of Family and Preventive Medicine have shown a ... ultraviolet B (UVB), and breast cancer. , UVB ... This form of vitamin D also is available through ...
    ... May 15 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... March 31, 2008. Pharmasset reported a net loss ... per share for the,quarter ended March 31, 2008, ...
    ... The following is a,statement from Larry Minnix, President ... Aging:, "Today,s GAO report points out yet again ... of nursing homes in this country. If,we want to ... need to,rethink our approach from the bottom up., ...
    ... Theranostics Health (THX) today,announced that it ... agreement with Duke University. This relationship will,provide ... technologies: Laser,Capture Microdissection (LCM) and Reverse Phase ... technologies provides a powerful,mechanism to accurately and ...
    Cached Medicine News:Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8Health News:Theranostics Health Signs Research Collaboration Agreement 2
    Plus cylinders only trial lens set....
    Trial Lens Sets....
    70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
    ... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
    Medicine Products: